Clarient to Announce 2010 Second Quarter and Six-Month Financial Results on Wednesday, July 28, 2010

ALISO VIEJO, Calif., July 20 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it will report its financial results for the second quarter and six months ended June 30, 2010 after the stock market closes on Wednesday, July 28.  

Date: Wednesday, July 28, 2010

Start Time: 5:00 p.m. EDT

Call-in Number: 1-888-846-5003 (U.S.) / +1-480-629-9860 (International)

Conference ID Number: 4331129

Webcast: www.clarientinc.com/investor

Web Replay: For those unable to participate in the live broadcast, a replay of the webcast will be archived at www.clarientinc.com/investor shortly after the call, and will be available for one year.

Speakers: Ron Andrews, Vice Chairman and CEO; Michael Pellini, MD, President and COO; Michael Rodriguez, CFO

Format: Presentation of second quarter and six month 2010 financial results followed by Q&A

About Clarient  

Clarient combines innovative diagnostic technologies with world class pathology expertise to assess and characterize cancer.  Clarient's mission is to become the leader in cancer diagnostics by dedicating itself to collaborative relationships with the healthcare community to translate cancer discovery and research into better patient care.  Clarient's principal customers include pathologists, oncologists, hospitals, and biopharmaceutical companies.  The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies, such as flow cytometry and molecular testing.  Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and diagnostic services.  Clarient's customers are connected to its Internet-based portal, PATHSITE® that delivers high resolution images and critical interpretive reports based on our diagnostic testing.  Clarient also develops and markets new, proprietary "companion" diagnostic markers for therapeutics in breast, prostate, lung, ovarian, and colon cancers, and leukemia/lymphoma. www.clarientinc.com

SOURCE Clarient, Inc.